Published Data in Metastatic Pancreatic Cancer
Most patients have locally advanced and/or metastatic pancreatic cancer, resulting in a dismal 5 year survival rate of <5%. In patients with liver metastases from primary cancer of the pancreas, encouraging results on the use of SIR-Spheres® Y-90 resin microspheres as first-line therapy for treatment-refractory disease have been obtained from prospective and retrospective studies.2,3
In one study, median survival was 5.5 months but considerably longer (13.6 months) in the cohort of patients with resected primary tumours.2 The authors concluded that the combination of SIR-Spheres Y-90 resin microspheres and 5FU appears effective in controlling metastases from pancreatic cancer, with extra-hepatic progression and resection of the primary tumour dictating survival.
When used as salvage therapy in treatment-refractory metastatic pancreatic cancer, SIR-Spheres Y-90 resin microspheres may have the potential to prolong survival even in patients with progressive disease.4,5
1 Jemal A et al. 2010. CA Cancer J Clin 2010; 60: 277-300.
2 Gibbs P et al. BMC Cancer 2015; 15: 802.
3 Michl M et al. Oncology 2014; 86: 24-32.
4 Lo G et al. J Vasc Interv Radiol 2014: 25: 811.e823-824.
5 Kim AY et al. J Vasc Interv Radiol 2015; 26: e76.